Health
Pharmaceutical
US

Bioanalytical Systems

$1.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (3.38%) Today
-$0.12 (-6.03%) After Hours

Why Robinhood?

You can buy or sell BASI and other stocks, options, ETFs, and crypto commission-free!

About

Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. Read More The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Employees
235
Headquarters
West Lafayette, Indiana
Founded
1974
Market Cap
19.72M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
34.42K
High Today
$1.99
Low Today
$1.87
Open Price
$1.95
Volume
5.56K
52 Week High
$2.59
52 Week Low
$1.18

Collections

Health
Pharmaceutical
US
North America

News

Yahoo FinanceMay 1

The Smithers Avanza Toxicology Services Business Unit Acquired by Bioanalytical Systems, Inc. “BASi”

AKRON, Ohio--(BUSINESS WIRE)-- The Smithers Avanza Toxicology Services business unit in Gaithersburg, MD, a boutique contract research organization (CRO) specializing in general toxicology, vaccine safety and developmental and reproductive toxicology (DART), announced today that it will be acquired by Bioanalytical Systems, Inc. (BASI) (“BASi” or the “Company”). The Smithers Avanza Bioanalytical Services business is not included in this sale. “Selling a business unit is never an easy decision, but we reco...

25

Earnings

-$0.06
-$0.03
$0.00
$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$0.06 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.